CNS drugs, 2013-08, Vol.27 (8), p.591-609
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
- Ist Teil von
- CNS drugs, 2013-08, Vol.27 (8), p.591-609
- Ort / Verlag
- Cham: Springer International Publishing
- Erscheinungsjahr
- 2013
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1172-7047eISSN: 1179-1934DOI: 10.1007/s40263-013-0080-zTitel-ID: cdi_proquest_miscellaneous_1560110042
- Format
- –
- Schlagworte
- Administration, Oral, Animals, Clinical trials, Clinical Trials as Topic, Drug administration, Drug Design, Drug dosages, FDA approval, Humans, Immunosuppressive Agents - administration & dosage, Immunosuppressive Agents - adverse effects, Immunosuppressive Agents - therapeutic use, Lymphocytes, Magnetic resonance imaging, Medicine, Medicine & Public Health, Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting - drug therapy, Multiple Sclerosis, Relapsing-Remitting - physiopathology, Neurology, Neurosciences, Oral diseases, Patients, Pharmacotherapy, Psychiatry, Psychopharmacology, Review Article, Time Factors